Zombie Cells: What Cellular Senescence Actually Is

Written by the Nuvirox Research Team

Short answer: senescence is real, well-characterised, and one of the better-supported hallmarks of aging — but the human intervention evidence is at the pilot stage. Cells that enter senescence permanently exit the cell cycle while remaining metabolically active, resist apoptosis, and adopt a secretory profile that spreads inflammatory signalling to neighbouring tissue. Clearing these cells improves function in mice, sometimes dramatically. In humans, the first trials showed senescent cell burden can be reduced and physical function can improve — in single-arm and open-label studies with fewer than 20 participants each. That is a real result and a thin foundation at the same time.

What is a senescent cell, exactly?

Cells enter senescence in response to stressors: telomere attrition after repeated division, DNA damage, oncogene activation, oxidative stress, and mitochondrial dysfunction. The response is a permanent cell cycle arrest. This is not a malfunction — it is an anti-cancer mechanism. A cell that has accumulated enough damage to be dangerous if it keeps dividing takes itself out of the game.

The problem is what comes next. A senescent cell does not die and does not get efficiently cleared. It stays, metabolically active, upregulating anti-apoptotic pathways that make it unusually resistant to the normal signals that would remove it. The nickname 'zombie cell' captures the situation reasonably well.

What makes them consequential is the senescence-associated secretory phenotype, or SASP: a heterogeneous package of inflammatory cytokines, chemokines, growth factors, proteases, extracellular vesicles, and microRNAs. The SASP remodels the surrounding tissue, recruits immune cells, and can induce senescence in neighbouring healthy cells. A small population can therefore have effects out of proportion to its size. This is a major contributor to what researchers call inflammaging — the chronic, low-grade inflammatory state that accompanies aging. The connection to NAD⁺ and inflammation is an active research area.

How does this relate to the other hallmarks of aging?

Senescence is one of the twelve entries in the updated hallmarks-of-aging framework, and it is unusually well-connected to the others. Telomere attrition triggers it. Genomic instability triggers it. Mitochondrial dysfunction both triggers it and is worsened by it. And senescent cells display altered NAD⁺ metabolism — CD38, an NAD⁺-consuming enzyme, is upregulated by SASP factors, which is one proposed mechanism linking inflammation to declining NAD⁺ availability with age.

That link is mechanistically interesting and should not be oversold. The observation that senescence and NAD⁺ decline are connected does not establish that raising NAD⁺ clears senescent cells, and the human evidence for that specific claim does not exist. For the honest version of what is and isn't established about the precursor itself, see whether NAD⁺ really declines with age and the telomere evidence.

What human senolytic trials actually found

The first-in-human trial was in idiopathic pulmonary fibrosis. Justice and colleagues ran an open-label pilot of intermittent dasatinib plus quercetin in 14 patients with IPF, a progressive and ultimately fatal senescence-associated disease. Short-term, intermittent administration was associated with clinically meaningful improvements in mobility measures. It was open-label, uncontrolled, and small — the authors framed it explicitly as a feasibility study supporting larger randomized trials.

The diabetic kidney disease pilot showed senescent cells could actually be reduced. Hickson and colleagues gave three days of oral dasatinib 100 mg plus quercetin 1,000 mg to nine subjects with diabetic kidney disease and demonstrated reduced senescent cell burden in adipose tissue. This was the first peer-reviewed demonstration that senolytics decrease senescent cells in humans. Nine participants, open-label, phase 1.

The cognition pilot was more equivocal. A single-arm study in older adults at risk for Alzheimer's disease with mild cognitive impairment and slow gait gave dasatinib 100 mg plus quercetin 1,250 mg for two days every two weeks over 12 weeks, assessing feasibility, safety, and preliminary functional and biomarker changes. Single-arm designs cannot separate treatment effect from practice effects, regression to the mean, or expectation — which is exactly why the authors positioned it as a pilot.

An honest counterweight from the bench. A 2025 GeroScience paper examining chromatin structure found that while dasatinib plus quercetin produced signs of chromatin rejuvenation in senescent vascular smooth muscle cells, it also induced some changes characteristic of senescence in young cells. Selectivity is not absolute, and that is a meaningful caution for anything approaching chronic use.

What about the quercetin in supplements?

This deserves a direct answer because the overlap invites confusion. Quercetin is a flavonoid found in onions, apples, capers, and Sophora japonica, and it appears in many supplement formulations — including NAD⁺ formulas that use it — typically in the range of 50 to 500 mg daily.

The senolytic protocols are structurally different in three ways. The dose is higher: 1,000 to 1,250 mg. The schedule is intermittent rather than daily: two or three days, then weeks off. And critically, quercetin in these trials is never used alone — it is paired with dasatinib, a prescription tyrosine kinase inhibitor used in leukaemia treatment. The combination targets different anti-apoptotic pathways in different senescent cell types, and there is no human trial establishing that quercetin by itself at supplement doses clears senescent cells.

What senolytics won't do, and what to be careful about

Dasatinib is a chemotherapy agent with a documented adverse effect profile including myelosuppression, fluid retention, pleural effusion, QT prolongation, and bleeding risk. Short intermittent dosing appears more favourable than continuous oncology dosing, but this is not a benign compound and self-administration is not a reasonable plan. It is also a CYP3A4 substrate with meaningful interaction potential.

Quercetin at high doses has its own considerations, including effects on drug-metabolising enzymes and potential interaction with anticoagulants. Anyone on warfarin should be aware that supplement ingredients can shift anticoagulant effect — a caution that applies to several common supplement ingredients and warrants an explicit conversation with the prescriber rather than an assumption.

Finally, senescence is not uniformly bad. It suppresses tumour formation and plays necessary roles in wound healing, tissue remodelling, and embryonic development. A therapy that eliminated senescence entirely and permanently would not obviously be desirable. The research question is selective clearance of accumulated, dysfunctional populations — which is harder and less marketable than 'kill zombie cells'.

Frequently asked questions

Can I buy a senolytic supplement?

Products marketed as senolytics typically contain fisetin, quercetin, or similar flavonoids. Fisetin is in clinical trials and the early data are not yet mature; quercetin has no standalone human senolytic evidence at supplement doses. Marketing has moved considerably faster than the trials.

How many senescent cells do I have?

There is no validated, accessible clinical test. Research studies measure senescent cell burden in tissue biopsies using markers like p16 and senescence-associated beta-galactosidase. Consumer biological age tests do not measure this.

Does exercise clear senescent cells?

Exercise reduces markers associated with senescence in some studies and has robust benefits through many other pathways. Whether it specifically clears senescent cells in humans is not firmly established, but it remains the intervention with by far the strongest overall evidence base.

Is fisetin better than quercetin?

Fisetin has shown senolytic activity in preclinical work and is under clinical investigation, with some researchers considering it more potent and better tolerated. Human efficacy data are still limited, so 'better' is premature.

How does this connect to NAD+ supplements?

There is a mechanistic link through CD38 and inflammaging, but no human trial has shown that NAD+ precursors clear senescent cells. These are adjacent research areas, not the same intervention.

The bottom line

Cellular senescence is one of the better-characterised hallmarks of aging, and the mechanism — cells that stop dividing, resist dying, and leak inflammatory signals into the tissue around them — is real and consequential. What is not yet established is that any available intervention safely and selectively clears them in humans over the long term. The first-in-human trials are genuinely encouraging and enrolled nine and fourteen people respectively. That is a beginning, not a conclusion, and the honest position is to find the biology fascinating while treating the product claims built on it with considerable scepticism.

References

1. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. DOI: 10.1016/j.ebiom.2019.08.069.
2. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. PMCID: PMC6845774.
3. Gonzales MM, Garbarino VR, Marques Zilli E, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. EBioMedicine. 2025. PMCID: PMC11907475.
4. Kirkland JL, Tchkonia T. Strategies for late phase preclinical and early clinical trials of senolytics. Mech Ageing Dev. 2021;200:111591. PMID: 34699859.
5. Gadecka A, Nowak N, et al. The senolytic cocktail, dasatinib and quercetin, impacts the chromatin structure of both young and senescent vascular smooth muscle cells. GeroScience. 2025;47(3):3907-3925. DOI: 10.1007/s11357-024-01504-6.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.